loader2
Partner With Us NRI

Neuland Laboratories Ltd share Price Today

Company details

6,411.00
6,798.45
1,950.00
7,318.30
6M Return 72.75%
1Y Return 215.45%
Mkt Cap.(Cr) 8,551.71
Volume 115,541
Div Yield 0.15%
OI
-
OI Chg %
-
Volume 115,541

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Neuland Laboratories announced Q3FY24 & 9MFY24 results:

Q3FY24 vs Q4FY23:

  • Total Income: Rs 394.9 crore, showing a growth of 46.2% compared to Q3FY23.
  • EBITDA: Rs 122.7 crore, increased significantly by 123.5% from Q3FY23.
  • EBITDA Margin: 31.1%, improved by 1080 basis points (bps) from Q3FY23.
  • PAT: Rs 80.7 crore, showing a substantial growth of 165.1% compared to Q3FY23.
  • PAT Margin: 20.4%, increased by 910 bps from Q3FY23.
  • EPS (Basic): Rs 62.9, reflecting a growth of 165.1% compared to Q3FY23.

9MFY24 vs 9MFY23:

  • Total Income: Rs 1,180.8 crore, increased significantly by 50.3% compared to 9MFY23.
  • EBITDA: Rs 362.3 crore, showing a substantial growth of 136.4% compared to 9MFY23.
  • EBITDA Margin: 30.7%, improved by 1120 bps from 9MFY23.
  • PAT: Rs 232.0 crore, showing a substantial growth of 195.1% compared to 9MFY23.
  • PAT Margin: 19.6%, increased by 960 bps from 9MFY23.
  • EPS (Basic): Rs 180.8, reflecting a growth of 195.1% compared to 9MFY23.

Commenting on the performance Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, “We are pleased to report another quarter of strong YoY topline growth of 46% to Rs 395 crore. The EBITDA margin of 31.1% is a factor of the business mix as well as improved operational leverage. Even as we see this as a validation of Neuland’s business model, we are focused on continuously improving operations across the company. We are investing both on infrastructure and our people so that we can deliver on our long-term plans.”

In addition, Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories added “Our CMS business saw healthy growth led by commercial as well as projects close to commercialization. The increasing interest from customers with exciting pipelines establishes Neuland’s reputation as a well regarded CDMO. As the quality and size of our business grows, we are gaining a better visibility of our future and planning accordingly.”

Result PDF

View Other Company Results

Neuland Laboratories Ltd shares SWOT Analysis

Strengths (10)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Rising Net Cash Flow and Cash from Operating activity
  • Company with high TTM EPS Growth

Weakness (0)

Data not found

Opportunity (4)

  • Companies with current TTM PE Ratio less than 3 Year, 5 Year and 10 Year PE
  • Highest Recovery from 52 Week Low
  • RSI indicating price strength

Threats (2)

  • Promoter decreasing their shareholding
  • Companies with growing costs YoY for long term projects

Resistance and support

R1 6,838.9
R2 7,012.4
R3 7,226.4
Pivot

6,624.95

S1 6,451.5
S2 6,237.5
S3 6,064.0
EMA SMA
6,351.7
6,297.2
5,884.8
5,026.1
6,220.1
6,534.0
5,974.1
4,854.3
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
RAMAMOHAN RAO DAVULURI Bulk Sell 2023-12-08 5012.45 400000 BSE
BNP PARIBAS ARBITRAGE Bulk Sell 2023-08-31 3871.31 64893 NSE
GRAVITON RESEARCH CAPITAL LLP Bulk Purchase 2023-05-15 2858.76 73921 NSE
Name Category Shares
RAMAMOHAN RAO DAVULURI PROMOTER 21.59%
DAVULURI VIJAYA RAO PROMOTER 4.78%
DAVULURI SUCHETH RAO PROMOTER 2.63%
DAVULURI SAHARSH RAO PROMOTER 2.24%
DAVULURI ROHINI NIVEDITHA RAO PROMOTER 0.67%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Neuland Laboratories Ltd Stocks COMPARISON

Financials( in Cr) Neuland Laboratories Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Dr Reddys Laboratories Ltd Divis Laboratories Ltd
Price 6,665.40 1,540.00 1,396.80 6,083.85 3,779.70
% Change 7.67 -3.99 -1.84 -1.20 1.09
Mcap Cr 8,551.71 369,497.59 112,770.65 101,484.09 100,339.32
Revenue TTM Cr 1,191.20 43,885.68 15,790.60 24,669.70 7,767.51
Net Profit TTM Cr 163.52 8,560.84 2,513.47 4,507.30 1,823.38
PE TTM 26.95 39.38 28.51 19.41 72.54
1 Year Return 215.45 52.69 54.88 27.82 29.90
ROCE 20.58 16.79 14.76 25.99 19.30
ROE 17.84 16.46 10.66 21.21 14.89
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 994.10 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 22,235.36 6,962.55
LAST 3M 82,992.21 54,903.33
LAST 6M 132,133.63 84,033.60
LAST 12M 206,189.80 211,987.34
Neuland Laboratories Limited - Disclosure under SEBI Takeover Regulations

Apr 09, 2024 l NSE Announcement

Neuland Laboratories Limited - Disclosure under SEBI Takeover Regulations

Apr 08, 2024 l NSE Announcement

Date Action Type Ratio
Jul 11, 2023 Dividend 100
Jul 14, 2022 Dividend 50

Neuland Laboratories Ltd Information

Stock PE (TTM)
26.95
Promoter Holding
32.8%
Book Value
882.2151
ROCE
20.58%
ROE
17.84%
Description
  • Set up in 1984 as a private limited company to manufacture bulk drugs, Neuland Laboratories (NLL) is promoted by D R Rao. Neuland Drugs & Pharmaceuticals Pvt Ltd, a company set up by the same promoters to manufacture bulk drugs was merged with NLL with effect from Apr.`92. NLL manufactures bulk drugs such as salbutamol sulphate, terbutaline sulphate, labetalol hydrochloride and ciprofloxacin. It came out with its initial public offering in Apr.`94 at a premium of Rs 35 aggregating Rs 5.69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix. The cost of the project as estimated by ICICI was Rs 15.7 cr. NLL`s products are exported to more than 35 countries including Germany, Italy, Switzerland, the UK and the Netherlands. The company is also negotiating with multinational companies for tying up supplies of Ranitidine Hydrochloride Form I and Salbutamol Sulphate. During the year 1999-2000, the company introduced Itraconazole, an anti-fungal drug and Ipratropium Bromide, an anti-asthmatic drug and the R & D has developed a process for manufacture of Oflaxacin for Regulatory Markets. The Pashamylaram unit has received USFDA approval for manufacturing of Rantidine Hydrochloride Form. Mirtrazapine, an anti-depressive drug and Ramipril a cardiovascular drug were introduced during the year 2001.The installed capacities of Ciprofloxacin and Ranitidine were increased with Rs.650 lacs financial assisitance from IDBI. The Company commenced commercial production of Ramipril, a cardiovascular drug for export to certain markets in 2002. The Company commenced commercial production of Citalopram Hydrobromide, an anti depressant, Pirbuterol Acetate, a bronchodilator, Levofloxacin, an anti bacterial, Levetiracetam, an anti convulsant in 2003. A subsidiary company of Neuland Laboratories Ltd was incorporated on January 4, 2007 in the State of Delaware, USA with its principal office in Orange County, California. During the year 2008-2009, Neuland Laboratories K.K., Japan was incorporated as a subsidiary of Company.

Registered Address

11 Th Floor Phoenix IVY Buildi, Plot No 573A-III Road No 82, Hyderabad, Telangana, 500035

Tel : 91-40-30211600
Email : ir:neulandlabs.com
Website : http://www.neulandlabs.com
Registrar

Karvy Computershare Pvt Ltd

AGM Date (Month) : Jul
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 524558
NSE Code : NEULANDLAB
Book Closure Date (Month) : Jul
BSE Group : A
ISIN : INE794A01010

FAQ’s on Neuland Laboratories Ltd Shares

You can buy Neuland Laboratories Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Neuland Laboratories Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Apr 12, 2024 04:05 PM the closing price of Neuland Laboratories Ltd was ₹ 6,665.40.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Apr 12, 2024 04:05 PM, the market cap of Neuland Laboratories Ltd stood at ₹ 8,551.71.

The latest PE ratio of Neuland Laboratories Ltd as of Apr 12, 2024 04:05 PM is 26.95

The latest PB ratio of Neuland Laboratories Ltd as of Apr 12, 2024 04:05 PM is 0.13

The 52-week high of Neuland Laboratories Ltd share price is ₹ 7,318.30 while the 52-week low is ₹ 1,950.00

Download Our

Download App
market app